5R-(+)-N-[(4-(trifluoromethyl)piperidin-1-yl)sulfonyl]-N'-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine | 1192739-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5R-(+)-N-[(4-(trifluoromethyl)piperidin-1-yl)sulfonyl]-N'-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine
• 英文别名: (R)-1-(4-chlorophenyl)-N-methyl-5-phenyl-N''-(4-(trifluoromethyl)piperidin-1-ylsulfonyl)-4,5-dihydro-1H-pyrazole-3-carboximidamide；(3R)-2-(4-chlorophenyl)-N'-methyl-3-phenyl-N-[4-(trifluoromethyl)piperidin-1-yl]sulfonyl-3,4-dihydropyrazole-5-carboximidamide
• CAS: 1192739-48-2
• 化学式: C₂₃H₂₅ClF₃N₅O₂S
• 分子量: 527.998
• InChiKey: RKNXIUHKWMPMBY-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  85.8
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-[(4-(trifluoromethyl)piperidin-1-yl)sulfonyl]-N'-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine 生成 5R-(+)-N-[(4-(trifluoromethyl)piperidin-1-yl)sulfonyl]-N'-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine 、 (3S)-2-(4-chlorophenyl)-N'-methyl-3-phenyl-N-[4-(trifluoromethyl)piperidin-1-yl]sulfonyl-3,4-dihydropyrazole-5-carboximidamide
  参考文献：
  名称：

  Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB1 receptor antagonists

  摘要：

  The synthesis, structure-activity relationship (SAR) studies and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles are described. The target compounds 6-18 represent a novel class of potent and selective CB1 receptor antagonists. Based on X-ray diffraction data, the orally active 17 is shown to elicit a different intramolecular H-bonding mode as compared to ibipinabant (3) and SLV330 (4). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.049

文献信息

• [EN] (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY<br/>[FR] DÉRIVÉS DE (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE AYANT UNE ACTIVITÉ ANTAGONISTE DE CB1
  申请人：SOLVAY PHARM BV

  公开号：WO2009130234A1

  公开（公告）日：2009-10-29

  This invention concerns (5R)-1,5-diaryl-4,5-dihydro-1 H-pyrazole-3-carboxamidine derivatives as cannabinoid-CB1 receptor antagonists, methods for the preparation of these compounds, novel intermediates useful for the synthesis of said dihydropyrazole derivatives, methods for the preparation of these intermediates, pharmaceutical compositions containing one or more of these dihydropyrazole derivatives as active ingredient, as well as the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders involving cannabinoid receptors. The compounds have the formula (I) wherein the symbols have the meanings given in the specification.

  这项发明涉及(5R)-1,5-二芳基-4,5-二氢-1H-吡唑烷-3-羧酰胺衍生物作为大麻素-CB1受体拮抗剂，这些化合物的制备方法，用于合成所述二氢吡唑烷衍生物的新型中间体，制备这些中间体的方法，包含一种或多种这些二氢吡唑烷衍生物作为活性成分的制药组合物，以及将这些制药组合物用于治疗涉及大麻素受体的精神和神经疾病。这些化合物的公式为(I)，其中符号在规范中给出了含义。
• (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY
  申请人：Lange Josephus H.M.

  公开号：US20110053983A1

  公开（公告）日：2011-03-03

  Embodiments of the invention relate to (5R)-1,5-diaryl-4,5-dihydro-1H-pyrazole-3-carboxamidine derivatives as cannabinoid-CB 1 receptor antagonists, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said dihydropyrazole derivatives, to methods for the preparation of these intermediates, pharmaceutical compositions containing one or more of these dihydropyrazole derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders involving cannabinoid receptors. The compounds of embodiments of the invention are compounds of formula (I) wherein the symbols have the meanings given in the specification.

  本发明实施例涉及作为大麻素-CB1受体拮抗剂的(5R)-1,5-二芳基-4,5-二氢-1H-吡唑烷-3-羧酰胺衍生物，制备这些化合物的方法，用于合成所述二氢吡唑烷衍生物的新中间体，制备这些中间体的方法，含有这些二氢吡唑烷衍生物作为活性成分的药物组合物，以及利用这些药物组合物治疗涉及大麻素受体的精神和神经疾病的用途。本发明实施例的化合物是式(I)的化合物，其中符号在说明书中给定的含义。